ArticleJournal of gastroenterology2026
A PRK-armed oncolytic adenovirus drives calreticulin exposure for dendritic cell licensing to prime antitumor CD8⁺ T cells and synergizes with anti-PD-1 or CAR-T therapy in colorectal cancer.
Yan Liu et al.PubMed ↗Publisher ↗
No numbers read from the abstract.